Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365525 | 0.82 | CYP3A4 (0.49) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542367 | 0.75 | CYP3A4 (0.62) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542324 | 0.75 | CYP3A4 (0.62) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542619 | 0.75 | CYP3A4 (0.67) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL2692577 | 0.74 | CYP3A4 (0.50) | CYP3A4 | |
| SCHEMBL1542811 | 0.73 | CYP3A4 (0.58) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL726323 | 0.73 | CYP3A4 (0.64) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542382 | 0.73 | CYP3A4 (0.59) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542738 | 0.73 | CYP3A4 (0.59) | CYP3A4TRPV1EPHX2NR1H4 | |
| SCHEMBL1542422 | 0.72 | CYP3A4 (0.59) | CYP3A4TRPV1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | claimed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | claimed |
| US-8168792-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ABBOT SARAH C | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226879-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, IFNAR1, RRM2B | CYP3A4 778/4885NR3C1 1143/4885TRPV1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.